Companies: 10,795·Total market cap: $144.5T
ChitogenX Inc.

ChitogenX Inc.

CHNXFOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$627628
P/E Ratio
52W High$0.0165
52W Low$0.0011
Overview

ChitogenX Inc.(CHNXF)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · CHNXF · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-0.02chnxf eps ttm · chnxf earnings per shareEarnings history
PE Ratio (TTM)chnxf pe ratio ttm · chnxf price to earningsPE Ratio deep dive
Revenue (TTM)0.00chnxf revenue ttm · chnxf annual revenueFull revenue history
Dividend Yield不分红does chnxf pay dividends · chnxf dividend yieldDividend history
Shares Outstanding73.0Mchnxf shares outstanding · chnxf floatShares outstanding history
Next EarningsJun 30, 2026Est.chnxf earnings date · chnxf next earningsEarnings history

财务快照

完整财报
FY 2024Revenue$0.00
202220232024
chitogenx inc. revenue · chnxf revenue 2024
FY 2024Net Income-$1.6M▲ +75.06% YoY
202220232024
chitogenx inc. net income · chnxf profit 2024
FY 2024EPS$-0.02▲ +83.62% YoY
202220232024
chnxf eps · chitogenx inc. earnings per share 2024
TTM:Revenue: $0.00Net Income: -$1.6MEPS: $-0.02View income statement →

股票表现

完整历史
1D+0.00%
1W+0.00%
1M+0.00%
3M+0.00%
YTD+0.00%
1Y+51.00%
5Y-97.65%

关于 ChitogenX Inc.

CEOPierre Laurin
IPO DateOct 6, 2020
Employees5
CountryCA

ChitogenX Inc. is a biologics firm focused on orthopedic and sports medicine, committing its efforts to pioneering novel soft tissue repair technologies. The company's primary objective is to elevate …

what is chitogenx inc. · chnxf stock overview · chitogenx inc. company profile · who is chitogenx inc. ceo · chnxf OTC · chitogenx inc. headquarters · chitogenx inc. business segments

关于股票概览与关键数据

ChitogenX Inc.(CHNXF)是 Biotechnology 行业的 Healthcare 类公司,于 Oct 6, 2020 在 OTC 上市。截至最近交易日,CHNXF 股价为 $0.01,市值约为 $627,628。过去12个月累计回报 +51.00%,年初至今回报 +0.00%。

2024 财年 ChitogenX Inc. 营收 —。完整财务数据(营收历史、盈利、资产负债表)请使用上方标签页。

常见问题

截至最近一个交易日,ChitogenX Inc.(CHNXF)股价为 $0.01,在 OTC 上市,52周区间为 $0.00 – $0.02。

CHNXF 最新股价CHNXF quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 9, 2026本内容不构成投资建议